Table 1:

Summary of characteristics of patients included in the MENTOR study.^a

	Rituximab	Cyclosporine
Age, years (SD)	51.9 (12.6)	52.2 (12.4)
Sex, male: % (no.)	72% (47)	82% (53)
Creatinine clearance, ml/min/1.73 m2 (SD)	84.9 (29.8)	87.4 (34.4)
Median serum albumin, mg/dl (interquartile range)	2.5 (2.1–2.9)	2.5 (2.1–2.9)
Median urinary protein, g/24 h (interquartile range)	8.9 (6.8–12.3)	8.9 (6.7–12.9)
Prior treatment with immunosuppressive therapy, % (no.)	29% (19)	31% (20)
Anti-phospholipase A2 antibody positive, % (no.)	77% (50)	71% (46)

^aData adapted from Fervenza et al. NEJM (2019) [5].